Equities

Cumberland Pharmaceuticals Inc

CPIX:NSQ

Cumberland Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.28
  • Today's Change0.03 / 2.40%
  • Shares traded13.91k
  • 1 Year change-39.34%
  • Beta0.2065
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.

  • Revenue in USD (TTM)37.79m
  • Net income in USD-10.38m
  • Incorporated1999
  • Employees91.00
  • Location
    Cumberland Pharmaceuticals Inc2525 W End Ave Ste 950NASHVILLE 37203-1608United StatesUSA
  • Phone+1 (615) 255-0068
  • Fax+1 (615) 255-0094
  • Websitehttps://www.cumberlandpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Healthy Extracts Inc2.88m-1.37m11.26m----28.14--3.91-0.4725-0.47250.98450.13361.120.665428.03---53.40-53.78-168.81-146.6567.8345.68-47.73-87.530.2059-0.91530.7131--10.41105.93-151.54------
NDT Pharmaceuticals Inc-100.00bn-100.00bn11.84m1.00--0.0661----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Aptorum Group Ltd431.38k-2.82m12.15m3.00--0.463--28.16-0.9126-0.91260.09544.800.020830.363.88143,793.30-20.92-40.45-19.62-42.362.45-4.04-1,006.30-1,233.681.18--0.1694---66.712.3871.18---78.15--
Guardion Health Sciences Inc6.43m-5.93m13.45m9.00--0.9778--2.09-4.614.975.0410.710.44672.748.20714,121.10-41.22-77.90-45.86-86.5544.8642.45-92.26-176.9316.59-2.980.00--10.8567.03101.00---58.56--
Aytu Biopharma Inc93.76m-13.68m14.75m150.00--0.4469--0.1573-2.65-2.6518.215.530.67922.422.93625,053.30-9.91-33.56-25.58-52.8165.3256.89-14.60-73.810.69230.2160.352--11.1096.5684.33------
Pharmacyte Biotech Inc0.00-17.24m14.82m2.00--0.5611-----1.93-1.930.004.920.00----0.000.5012-7.420.5333-7.68------------0.00-------299.38------
Talphera Inc398.00k-13.70m15.29m15.00--1.20--38.43-0.6353-0.63230.01850.74910.0187----26,533.33-64.37-22.60-78.11-28.55-----3,443.22-714.87----0.00-----21.26-119.16---34.33--
Cara Therapeutics Inc11.00m-111.08m15.69m55.00--1.35--1.43-2.04-2.040.20170.21150.10631.102.10199,927.30-107.38-35.76-132.61-40.8274.66---1,010.20-162.104.48--0.00---49.929.26-38.65--100.66--
DH Enchantment Inc100.00-173.19k16.09m1.00------160,915.00-0.0002-0.00020.00-0.00120.04380.1493--100.00-7,579.43------0.00---173,190.00--0.0029-14.85-----95.43--59.53------
Nexgel Inc5.01m-3.39m17.19m19.00--3.85--3.43-0.5722-0.57220.84640.65890.49423.036.44263,631.60-35.74-44.61-48.15-56.1923.745.02-72.33-180.980.8135--0.1992--99.6613.0633.48------
Cumberland Pharmaceuticals, Inc.37.79m-10.38m17.62m91.00--0.6681--0.4663-0.7328-0.73282.671.870.45010.86433.17415,225.80-12.35-7.03-17.75-9.5282.5879.95-27.45-17.641.26-38.850.382---5.856.15-12.73---36.17--
Cyclo Therapeutics Inc1.13m-20.74m18.68m8.00------16.50-0.9104-0.91040.0474-0.17850.2420.400213.16141,553.80-443.08-132.22---215.1791.5690.37-1,831.29-1,114.040.4283-------21.761.25-29.81---3.95--
TherapeuticsMD Inc996.00k-4.83m19.14m1.00--0.6918--19.22-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Polypid Ltd0.00-24.70m24.26m59.00--10.34-----9.65-9.650.000.33370.00----0.00-107.89-76.92-164.39-89.61-----------24.210.8425------39.67---42.34--
Data as of Sep 19 2024. Currency figures normalised to Cumberland Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

14.03%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 30 Jun 2024538.16k3.82%
The Vanguard Group, Inc.as of 30 Jun 2024374.25k2.66%
Bridgeway Capital Management LLCas of 30 Jun 2024286.66k2.03%
Dimensional Fund Advisors LPas of 30 Jun 2024285.34k2.02%
Acadian Asset Management LLCas of 30 Jun 2024188.16k1.34%
Geode Capital Management LLCas of 30 Jun 202488.75k0.63%
BlackRock Fund Advisorsas of 30 Jun 202481.97k0.58%
Newton Investment Management North America LLCas of 30 Jun 202471.84k0.51%
SSgA Funds Management, Inc.as of 30 Jun 202433.70k0.24%
BlackRock Financial Management, Inc.as of 30 Jun 202428.59k0.20%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.